The TGA published details of the discontinuation on the TGA Medicines Shortages website on 30 September 2014. Since this time the TGA has been working with sponsors and professional bodies to ensure health professionals are informed about the discontinuance. We have also been working to identify alternative products.
Prostin F2 Alpha (dinoprost trometamol) is used in evacuating the uterus in cases of foetal death and the therapeutic termination of pregnancy and it is also used for the non-surgical treatment for the evacuation of hydatidiform moles. Prostaglandin F2 Alpha (dinoprost trometamol) is also used in obstetric facilities for the treatment of severe postpartum haemorrhage. Clinicians are referred to The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) College Statements and Guidelines for the Management of Postpartum Haemorrhage. Prostaglandin F2 Alpha (dinoprost trometamol) is only used in hospitals or locations with facilities for emergency obstetric and gynaecological care.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse events associated with a medicine, vaccine or medical device.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.